31 results on '"Erra, Alba"'
Search Results
2. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
- Author
-
Julià, Antonio, López-Lasanta, María, Blanco, Francisco, Gómez, Antonio, Haro, Isabel, Mas, Antonio Juan, Erra, Alba, Vivar, Ma Luz García, Monfort, Jordi, Sánchez-Fernández, Simón, González, Isidoro, Alperi, Mercedes, Castellanos-Moreira, Raúl, Fernández-Nebro, Antonio, Díaz-Torné, César, Palau, Núria, Lastra, Raquel, Lladós, Jordi, Sanmartí, Raimon, and Marsal, Sara
- Published
- 2021
- Full Text
- View/download PDF
3. Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation
- Author
-
de Agustín, Juan José, Erra, Alba, Ponce, Andrés, Moragues, Carmen, Díaz-Torné, Cesar, Reina, Delia, Moreno, Estefanía, Ramírez, Julio, Mateo, Lourdes, Pujol Busquets, Manel, Moya, Patricia, Santo-Panero, Pilar, Ros-Expósito, Sergi, Narváez, Javier, Sanmartí, Raimon, García de Yébenes, Mª Jesús, and Carmona, Loreto
- Published
- 2019
- Full Text
- View/download PDF
4. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
- Author
-
de Rábago, Eugenia Gonzalez, Blanco Morales, Elena Alonso, Fernández López, J. Carlos, Villar, Natividad Oreiro, Sandoval, Antonio Atanes, Blanco García, Francisco J., De Miquel, Cayetano Alegre, González Fernández, María J., Codina, Ramón Huguet, Yoldi, Beatriz, Ramentol, Mercedes, Ávila, Gabriela, Barril, Sara Marsal, Steiner, Martina, Muñoz, Santiago, Gamero, Fernando, Torón, José García, Moreno Gil, María P., Mas, Antonio J., Espiño, Pilar, Ros, Inmaculada, Ibañez, Mónica, Murillo, Claudia, Piqueras, José A., Sanmartí, Raimon, Berman, Horacio, Cabrera, Sonia, Ruiz, Virginia, Patón, Oscar Fontseré, Gutiérrez, Benjamín Fernández, Abasolo, Lydia, Fábregas, María D., Nolla, Joan M., Arias, Miriam García, García Vadillo, Jesús A., de Vicuña, Rosario García, Nebro, Antonio Fernández, Belmonte López, Maria Angeles, Ureña, Inmaculada, Irigoyen, María V., Cagigal, Virginia Coret, González, Ruth López, Garrido, Daniel Pielfort, Alvarez, Juana Sampedro, García Aparicio, Ángel María, Gómez, Rebeca Belmonte, Bautista, Pastora Granados, Sanz, Azucena Hernández, Sánchez González, Carmen O., Bachiller, Javier, Zea, Antonio, Manero, Francisco J., Zorzo, Fernando Jimenez, Ubeda, Eugenio Giménez, Gracía, Jesús Marzo, Audera, Chesús Beltrán, Medrano, Marta, Pecondón, Ángela, Erausquin, Celia, Ojeda, Soledad, Quevedo, Juan Carlos, Francisco, Félix, Lozano, Carlos Rodríguez, Herráez, Jesús Babío, López Longo, Francisco J., Gerona, Delia, Fernández, Carlos González, Carreño, Luis, Monteagudo, Indalecio, del Pino, Javier, Sánchez González, María Dolores, Corrales, Alfonso, Peiró, María Enriqueta, Senabre, José M., Rosas, José C., Rotés, Isabel, Moreno, Estefanía, Erra, Alba, Grado, Dolors, Calvo, Javier, Rueda, Amalia, Möller, Ingrid, Rodríguez, Isabel, Barbadillo, Carmen, Raya, Enrique, Morales, Pilar, Nieto, Ana, Jiménez, Inmaculada, magro, Cesar, Escribano, Ana Ruibal, Expósito, Sergio Ros, Nievas, Ginés Sánchez, Navarro, Enrique Júdez, Fernández, Manuela Sianes, García Morales, María Ángeles, Bastero, Isabel Labiano, Consuegra, Gloria García, Palmou, Natalia, Pardo, Silvia Martínez, Pujol, Manel, Alonso, Elena Riera, Salvador, Georgina, Alvarez, Beatriz González, Cantabrana, Alberto, Bustabad, Sagrario, Delgado, Esmeralda, Muñoz, Alejandro, Montero, Sergio Rodríguez, Jiménez, Luis María, Redondo, Javier Rivera, Hernández, Teresa González, González Polo, Francisco J., Almagro, Raúl Menor, Moreno, José M., Serret, Emilio Giner, Barroso, Carla Lannuzzelli, Méndez, Laura Cebrián, Navío, María Teresa, Carballido, Cristina Fernández, Pagán, Encarnación, del Castillo, Pablo Mesa, Naredo, Esperanza, Cruz, Ana, Turrión, Ana, Mateo, Isabel, Sánchez, Julio, Galindo, María, González, Javier García, Collantes, Eduardo, Ruíz, Desireé, Font, Pilar, Bonilla, Gema, Meseguer, Antonio López, Moreno, Manuel J., Martínez, M<ce:sup loc='post">a</ce:sup> José Moreno, Fernández, M<ce:sup loc='post">a</ce:sup> Dolores Beteta, Linares, Luis F., Morcillo, Mercedes, González Gómez, María L., Aramburu, José M., Rivera, Natalia A., Berrizbeitia, Olaia Fernández, García Vivar, María Luz, Riera, Manel, León, Yolanda María, Maymó, Joan, Amirall, Miriam, Escolano, Silvia Iniesta, Serrano, Silvia Sánchez, Lis Bona, María Pilar, Fiter, Jordi, Melón, Julia Fernández, Espadaler, Luis, Maiz, Olga, Belzunegui, Joaquín, Bañegil, Inmaculada, Díaz, César, Valls, Ramón, Castellví, Iván, Bonet, María, Ruzafa, Estefania Moreno, Alen, Jaime Calvo, Sandoval, Trinidad Pérez, Evrard, Eva Revuelta, Godo, Javier R., Espartero, Cruz Fernández, Navarro Blasco, Francisco J., González, José Antonio, Miranda-Filloy, José A., García-Gómez, Carmen, Martín-Martínez, Maria A., Castañeda, Santos, Sanchez-Alonso, Fernando, Uriarte-Ecenarro, Miren, González-Juanatey, Carlos, Romera-Baures, Montserrat, Santos-Rey, José, Pinto-Tasende, José Antonio, Quesada-Masachs, Estefanía, Tornero-Molina, Jesús, Martínez-González, Olga, Cobo-Ibáñez, Tatiana, Chamizo-Carmona, Eugenio, Manrique-Arija, Sara, Fábregas-Canales, Dolores, Díaz-González, Federico, Llorca, Javier, and González-Gay, Miguel A.
- Published
- 2017
- Full Text
- View/download PDF
5. Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies
- Author
-
Corominas, Hèctor, Ortiz-Santamaría, Vera, Castellví, Iván, Moreno, Mireia, Morlà, Rosa, Clavaguera, Teresa, Erra, Alba, Martínez-Pardo, Silvia, Ordóñez, Sergi, Santo, Pilar, Reyner, Patricia, González, Maria José, Codina, Oriol, Gelman, Mario Saul, Juanola-Roura, Xavier, Olivé, Alex, Torrente-Segarra, Vicenç, and CapiCAT group
- Published
- 2016
- Full Text
- View/download PDF
6. Identification of IRX1 as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study
- Author
-
Julià, Antonio, Blanco, Francisco, Fernández-Gutierrez, Benjamín, González, Antonio, Cañete, Juan D., Maymó, Joan, Alperi-López, Mercedes, Olivè, Alex, Corominas, Héctor, Martínez-Taboada, Víctor, González-Álvaro, Isidoro, Fernandez-Nebro, Antonio, Erra, Alba, Sánchez-Fernández, Simón, Alonso, Arnald, López-Lasanta, María, Tortosa, Raül, Codó, Laia, Lluis Gelpi, Josep, García-Montero, Andrés C., Bertranpetit, Jaume, Absher, Devin, Myers, Richard M., Tornero, Jesús, and Marsal, Sara
- Published
- 2016
- Full Text
- View/download PDF
7. Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry.
- Author
-
Michelena, Xabier, López-Medina, Clementina, Erra, Alba, Juanola, Xavier, Font-Ugalde, Pilar, Collantes, Eduardo, and Marzo-Ortega, Helena
- Published
- 2022
- Full Text
- View/download PDF
8. A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk
- Author
-
Julià, Antonio, Pinto, José Antonio, Gratacós, Jordi, Queiró, Rubén, Ferrándiz, Carlos, Fonseca, Eduardo, Montilla, Carlos, Torre-Alonso, Juan Carlos, Puig, Lluís, Pérez Venegas, José Javier, Fernández Nebro, Antonio, Fernández, Emilia, Muñoz-Fernández, Santiago, Daudén, Esteban, González, Carlos, Roig, Daniel, Sánchez Carazo, José Luís, Zarco, Pedro, Erra, Alba, López Estebaranz, José Luís, Rodríguez, Jesús, Ramírez, David Moreno, de la Cueva, Pablo, Vanaclocha, Francisco, Herrera, Enrique, Castañeda, Santos, Rubio, Esteban, Salvador, Georgina, Díaz-Torné, César, Blanco, Ricardo, Willisch Domínguez, Alfredo, Mosquera, José Antonio, Vela, Paloma, Tornero, Jesús, Sánchez-Fernández, Simón, Corominas, Héctor, Ramírez, Julio, López-Lasanta, María, Tortosa, Raül, Palau, Nuria, Alonso, Arnald, García-Montero, Andrés C, Gelpí, Josep Lluís, Codó, Laia, Day, Kenneth, Absher, Devin, Myers, Richard M, Cañete, Juan D, and Marsal, Sara
- Published
- 2015
- Full Text
- View/download PDF
9. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis
- Author
-
Julià, Antonio, Rodríguez, Jesús, Fernández-Sueiro, José Luis, Gratacós, Jordi, Queiró, Rubén, Montilla, Carlos, Torre-Alonso, Juan Carlos, Pérez-Venegas, José Javier, Manrique-Arija, Sara, Muñoz-Fernández, Santiago, González, Carlos, Roig, Daniel, Zarco, Pedro, Erra, Alba, Castañeda, Santos, García, Alicia, Salvador, Georgina, Díaz-Torne, César, Blanco, Ricardo, Domínguez, Alfredo Willisch, Mosquera, José Antonio, Vela, Paloma, Tornero, Jesús, Sánchez-Fernández, Simón, Corominas, Héctor, Ramírez, Julio, Ávila, Gabriela, Alonso, Arnald, Tortosa, Raül, López-Lasanta, María, Cañete, Juan D, and Marsal, Sara
- Published
- 2014
- Full Text
- View/download PDF
10. GWAS replication study confirms the association of PDE3A–SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis
- Author
-
Acosta-Colman, Isabel, Palau, Núria, Tornero, Jesús, Fernández-Nebro, Antonio, Blanco, Francisco, González-Alvaro, Isidoro, Cañete, Juan D, Maymó, Joan, Ballina, Javier, Fernández-Gutiérrez, Benjamín, Olivé, Alex, Corominas, Héctor, Erra, Alba, Canela-Xandri, Oriol, Alonso, Arnald, López Lasanta, Maria, Tortosa, Raül, Julià, Antonio, and Marsal, Sara
- Published
- 2013
- Full Text
- View/download PDF
11. Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes
- Author
-
Julià, Antonio, Tortosa, Raül, Hernanz, José Manuel, Cañete, Juan D., Fonseca, Eduardo, Ferrándiz, Carlos, Unamuno, Pablo, Puig, Lluís, Fernández-Sueiro, José Luís, Sanmartí, Raimon, Rodríguez, Jesús, Gratacós, Jordi, Dauden, Esteban, Sánchez-Carazo, José Luís, López-Estebaranz, José Luís, Moreno-Ramírez, David, Queiró, Rubén, Montilla, Carlos, Torre-Alonso, Juan Carlos, Pérez-Venegas, José Javier, Vanaclocha, Francisco, Herrera, Enrique, Muñoz-Fernández, Santiago, González, Carlos, Roig, Daniel, Erra, Alba, Acosta, Isabel, Fernández-Nebro, Antonio, Zarco, Pedro, Alonso, Arnald, López-Lasanta, María, García-Montero, Andrés, Gelpí, Josep Lluís, Absher, Devin, and Marsal, Sara
- Published
- 2012
- Full Text
- View/download PDF
12. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells
- Author
-
Julià, Antonio, Barceló, Mireia, Erra, Alba, Palacio, Carles, and Marsal, Sara
- Published
- 2009
- Full Text
- View/download PDF
13. Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility
- Author
-
Julià, Antonio, Ballina, Javier, Cañete, Juan D., Balsa, Alejandro, Tornero-Molina, Jesus, Naranjo, Antonio, Alperi-López, Mercedes, Erra, Alba, Pascual-Salcedo, Dora, Barcel, Pere, Camps, Jordi, and Marsal, Sara
- Published
- 2008
14. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
- Author
-
Carmona, Loreto, Descalzo, Miguel Ángel, Perez-Pampin, Eva, Ruiz-Montesinos, Dolores, Erra, Alba, Cobo, Tatiana, and Gómez-Reino, Juan J
- Published
- 2007
15. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
- Author
-
Michelena, Xabier, Borrell, Helena, López-Corbeto, Mireia, López-Lasanta, María, Moreno, Estefanía, Pascual-Pastor, María, Erra, Alba, Serrat, Mayte, Espartal, Esther, Antón, Susana, Añez, Gustavo Adolfo, Caparrós-Ruiz, Raquel, Pluma, Andrea, Trallero-Araguás, Ernesto, Barceló-Bru, Mireia, Almirall, Miriam, De Agustín, Juan José, Lladós, Jordi, Julià, Antonio, and Marsal, Sara
- Abstract
• There is limited evidence on the potential risk conferred by tDMARDs with regards to COVID-19 in rheumatic disease patients. • COVID-19 incidence rates are similar to same district general population with no cases reported in the paediatric cohort. • tDMARDs should not be stopped during the pandemic and our findings encourage research with such treatments in COVID-19 disease. To investigate the incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases receiving targeted biologic and synthetic disease modifying anti-rheumatic drugs (tDMARDs) and to explore the possible effect of these treatments in the clinical expression of COVID-19. A cross-sectional study comprising of a telephone survey and electronic health records review was performed including all adult and paediatric patients with rheumatic diseases treated with tDMARDs in a large rheumatology tertiary centre in Barcelona, Spain. Demographics, disease activity, COVID-19 related symptoms and contact history data were obtained from the start of the 2020 pandemic. Cumulative incidence of confirmed cases (SARS-CoV-2 positive PCR test) was compared to the population estimates for the same city districts from a governmental COVID-19 health database. Suspected cases were defined following WHO criteria and compared to those without compatible symptoms. 959 patients with rheumatic diseases treated with tDMARDs were included. We identified 11 confirmed SARS-CoV-2 positive cases in the adult cohort and no confirmed positive cases in the paediatric cohort. COVID-19 incidence rates of the rheumatic patient cohort were very similar to that of the general population [(0.48% (95% CI 0.09 to 0.87%)] and [0.58% (95% CI 0.56 to 0.60%)], respectively. We found significant differences in tDMARDs proportions between the suspected and non-suspected cases (p =0.002). Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.
- Author
-
Bosch-Nicolau, Pau, Ubals, Maria, Salvador, Fernando, Sánchez-Montalvá, Adrián, Aparicio, Gloria, Erra, Alba, Martinez de Salazar, Pablo, Sulleiro, Elena, and Molina, Israel
- Subjects
TUMOR necrosis factors ,LEISHMANIASIS ,CUTANEOUS leishmaniasis ,MONOCLONAL antibodies ,DISEASE risk factors - Abstract
Background: Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation of granulomatous infections. Leishmaniasis has been associated with the use of these drugs, although few cases have been reported. Methodology: We performed a retrospective observational study including patients with confirmed leishmaniasis acquired in the Mediterranean basin that were under TNF-α blockers therapy at the moment of the diagnosis. Patients diagnosed in our hospital from 2008 to 2018 were included. Moreover, a systematic review of the literature was performed and cases fulfilling the inclusion criteria were also included. Principal findings: Forty-nine patients were analyzed including nine cases from our series. Twenty-seven (55.1%) cases were male and median age was 55 years. Twenty-five (51%) patients were under infliximab treatment, 20 (40.8%) were receiving adalimumab, 2 (4.1%) etanercept, one (2%) golimumab and one (2%) a non-specified TNF-α blocker. Regarding clinical presentation, 28 (57.1%) presented as cutaneous leishmaniasis (CL), 16 (32.6%) as visceral leishmaniasis (VL) and 5 (10.2%) as mucocutaneous leishmaniasis (MCL). All VL and MCL patients were treated with systemic therapies. Among CL patients, 13 (46.4%) were treated with a systemic drug (11 received L-AmB, one intramuscular antimonials and one miltefosine) while 14 (50%) patients were given local treatment (13 received intralesional pentavalent antimonials, and one excisional surgery). TNF-α blockers were interrupted in 32 patients (65.3%). After treatment 5 patients (10.2%) relapsed. Four patients with a CL (3 initially treated with local therapy maintaining TNF-α blockers and one treated with miltefosine) and one patient with VL treated with L-AmB maintaining TNF-α blockers. Conclusions: This data supports the assumption that the blockage of TNF-α modifies clinical expression of leishmaniasis in endemic population modulating the expression of the disease leading to atypical presentations. According to the cases reported, the best treatment strategy would be a systemic drug and the discontinuation of the TNF-α blockers therapy until clinical resolution. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
- Author
-
Aterido, Adrià, Cañete, Juan D., Tornero, Jesús, Blanco, Francisco, Fernández-Gutierrez, Benjamín, Pérez, Carolina, Alperi-López, Mercedes, Olivè, Alex, Corominas, Héctor, Martínez-Taboada, Víctor, González, Isidoro, Fernández-Nebro, Antonio, Erra, Alba, López-Lasanta, María, López Corbeto, Mireia, Palau, Núria, Marsal, Sara, and Julià, Antonio
- Subjects
RHEUMATOID arthritis ,GENE regulatory networks ,GENE therapy ,SEQUENTIAL analysis ,SYNOVIOMA ,THERAPEUTICS ,AUTOIMMUNE diseases - Abstract
Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. Methods: We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. Results: A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response (P < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab (P = 0.0015) and infliximab (P = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab (P = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism (P = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells (P = 0.041). Conclusions: These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.
- Author
-
Aterido, Adrià, Cañete, Juan D., Tornero, Jesús, Ferrándiz, Carlos, Pinto, José Antonio, Gratacós, Jordi, Queiró, Rubén, Montilla, Carlos, Torre-Alonso, Juan Carlos, Pérez-Venegas, José J., Nebro, Antonio Fernández, Muñoz-Fernández, Santiago, González, Carlos M., Roig, Daniel, Zarco, Pedro, Erra, Alba, Rodríguez, Jesús, Castañeda, Santos, Rubio, Esteban, and Salvador, Georgina
- Abstract
Objective: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis affecting up to 30% of patients with psoriasis (Ps). To date, most of the known risk loci for PsA are shared with Ps, and identifying disease-specific variation has proven very challenging. The objective of the present study was to identify genetic variation specific for PsA.Methods: We performed a genome-wide association study in a cohort of 835 patients with PsA and 1558 controls from Spain. Genetic association was tested at the single marker level and at the pathway level. Meta-analysis was performed with a case-control cohort of 2847 individuals from North America. To confirm the specificity of the genetic associations with PsA, we tested the associated variation using a purely cutaneous psoriasis cohort (PsC, n=614) and a rheumatoid arthritis cohort (RA, n=1191). Using network and drug-repurposing analyses, we further investigated the potential of the PsA-specific associations to guide the development of new drugs in PsA.Results: We identified a new PsA risk single-nucleotide polymorphism at B3GNT2 locus (p=1.10e-08). At the pathway level, we found 14 genetic pathways significantly associated with PsA (pFDR<0.05). From these, the glycosaminoglycan (GAG) metabolism pathway was confirmed to be disease-specific after comparing the PsA cohort with the cohorts of patients with PsC and RA. Finally, we identified candidate drug targets in the GAG metabolism pathway as well as new PsA indications for approved drugs.Conclusion: These findings provide insights into the biological mechanisms that are specific for PsA and could contribute to develop more effective therapies. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. Association Between Vitamin D Status and Schizophrenia: A First Psychotic Episode Study.
- Author
-
Salavert, José, Grados, Dolors, Ramiro, Nuria, Carrión, Maria Isabel, Fadeuilhe, Christian, Palma, Felipe, López, Laura, Erra, Alba, and Ramírez, Nicolás
- Published
- 2017
- Full Text
- View/download PDF
20. A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis.
- Author
-
Julià, Antonio, González, Isidoro, Fernández-Nebro, Antonio, Blanco, Francisco, Rodriguez, Luis, González, Antonio, Cañete, Juan D., Maymó, Joan, Alperi-López, Mercedes, Olivé, Alejandro, Corominas, Héctor, Martínez-Taboada, Víctor, Erra, Alba, Sánchez-Fernández, Simón, Alonso, Arnald, Lopez-Lasanta, Maria, Tortosa, Raül, Codó, Laia, Gelpi, Josep Lluis, and García-Montero, Andres C.
- Subjects
RHEUMATOID arthritis risk factors ,CONFIDENCE intervals ,GENETIC polymorphisms ,GENETICS ,JOINTS (Anatomy) ,RESEARCH funding ,DESCRIPTIVE statistics ,ODDS ratio ,GENOTYPES - Abstract
Objective. RA patients with serum ACPA have a strong and specific genetic background. The objective of the study was to identify new susceptibility genes for ACPA-positive RA using a genome-wide association approach. Methods. A total of 924 ACPA-positive RA patients with joint damage in hands and/or feet, and 1524 healthy controls were genotyped in 582 591 single-nucleotide polymorphisms (SNPs) in the discovery phase. In the validation phase, the most significant SNPs in the genome-wide association study representing new candidate loci for RA were tested in an independent cohort of 863 ACPA-positive patients with joint damage and 1152 healthy controls. All individuals from the discovery and validation cohorts were Caucasian and of Southern European ancestry. Results. In the discovery phase, 60 loci not previously associated with RA risk showed evidence for association at P<5x1CT
-4 and were tested for replication in the validation cohort. A total of 12 loci were replicated at the nominal level (P < 0.05, same direction of effect as in the discovery phase). When combining the discovery and validation cohorts, an intronic SNP in the Solute Carrier family 8 gene (SLC8A3) was found to be associated with ACPA-positive RA at a genome-wide level of significance RA [odds ratio (95% CI): 1.42 (1.25, 1.6), Pcombined = 3.19x10-8 ]. Conclusions. SLC8A3 was identified as a new risk locus for ACPA-positive RA. This study demonstrates the advantage of analysing relevant subsets of RA patients to identify new genetic risk variants. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. Reference intervals for bone turnover markers in Spanish premenopausal women.
- Author
-
Guañabens, Núria, Filella, Xavier, Monegal, Ana, Gómez-Vaquero, Carmen, Bonet, María, Buquet, Dolors, Casado, Enrique, Cerdá, Dacia, Erra, Alba, Martinez, Silvia, Montalá, Núria, Pitarch, Concepción, Kanterewicz, Eduardo, Sala, Miquel, Surís, Xavier, and Torres, Ferran
- Subjects
MENOPAUSE treatment ,PERIMENOPAUSE ,OSTEOPOROSIS ,URINE ,COLLAGEN - Abstract
Background: The aims of this study were to establish robust reference intervals and to investigate the factors influencing bone turnover markers (BTMs) in healthy premenopausal Spanish women. Methods: A total of 184 women (35-45 years) from 13 centers in Catalonia were analyzed. Blood and second void urine samples were collected between 8 a.m. and 10 a.m. after an overnight fast. Serum procollagen type I aminoterminal propeptide (PINP) and serum cross-linked C-terminal telopeptide of type I collagen (CTX-I) were measured by two automated assays (Roche and IDS), bone alkaline phosphatase (bone ALP) by ELISA, osteocalcin (OC) by IRMA and urinary NTX-I by ELISA. PTH and 25-hydroxyvitamin D (25OHD) levels were measured. All participants completed a questionnaire on lifestyle factors. Results: Reference intervals were: PINP: 22.7-63.1 and 21.8-65.5 μg/L, bone ALP: 6.0-13.6 μg/L, OC: 8.0-23.0 μg/L, CTX-I: 137-484 and 109-544 ng/L and NTX-I: 19.6-68.9 nM/mM. Oral contraceptive pills (OCPs) influenced PINP (p = 0.007), and low body mass index (BMI) was associated with higher BTMs except for bone ALP. Women under 40 had higher median values of most BTMs. CTX-I was influenced by calcium intake (p = 0.010) and PTH (p = 0.007). 25OHD levels did not influence BTMs. Concordance between the two automated assays for PINP and particularly CTX-I was poor. Conclusions: Robust reference intervals for BTMs in a Southern European country are provided. The effects of OCPs and BMI on their levels are significant, whilst serum 25OHD levels did not influence BTMs. Age, calcium intake, BMI and PTH influenced CTX-I. The two automated assays for measuring PINP and CTX-I are not interchangeable. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis.
- Author
-
Lopez-Lasanta, Maria, Julià, Antonio, Maymó, Joan, Fernández-Gutierrez, Benjamín, Ureña-Garnica, Inmaculada, Blanco, Francisco J., Cañete, Juan D., Alperi-López, Mercedes, Olivè, Alex, Corominas, Héctor, Tornero, Jesus, Erra, Alba, Almirall, Miriam, Palau, Nuria, Ortiz, Ana, Avila, Gabriela, Rodriguez-Rodriguez, Luis, Alonso, Arnald, Tortosa, Raül, and Gonzalez-Alvaro, Isidoro
- Published
- 2015
- Full Text
- View/download PDF
23. Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
- Author
-
Avila-Pedretti, Gabriela, Tornero, Jesús, Fernández-Nebro, Antonio, Blanco, Francisco, González-Alvaro, Isidoro, Cañete, Juan D., Maymó, Joan, Alperiz, Mercedes, Fernández-Gutiérrez, Benjamín, Olivé, Alex, Corominas, Héctor, Erra, Alba, Aterido, Adrià, López Lasanta, María, Tortosa, Raül, Julià, Antonio, and Marsal, Sara
- Subjects
BIOLOGICAL variation ,RHEUMATOID arthritis treatment ,TUMOR necrosis factors ,FC receptors ,INFLIXIMAB ,GENE expression ,MACROPHAGES ,SYNOVIAL fluid ,THERAPEUTICS - Abstract
Objective: Anti-TNF therapies have been highly efficacious in the management of rheumatoid arthritis (RA), but 25–30% of patients do not show a significant clinical response. There is increasing evidence that genetic variation at the Fc receptor FCGR2A is associated with the response to anti-TNF therapy. We aimed to validate this genetic association in a patient cohort from the Spanish population, and also to identify new genes functionally related to FCGR2A that are also associated with anti-TNF response. Methods: A total of 348 RA patients treated with an anti-TNF therapy were included and genotyped for FCGR2A polymorphism rs1081274. Response to therapy was determined at 12 weeks, and was tested for association globally and independently for each anti-TNF drug (infliximab, etanercept and adalimumab). Using gene expression profiles from macrophages obtained from synovial fluid of RA patients, we searched for genes highly correlated with FCGR2A expression. Tag SNPs were selected from each candidate gene and tested for association with the response to therapy. Results: We found a significant association between FCGR2A and the response to adalimumab (P=0.022). Analyzing the subset of anti-CCP positive RA patients (78%), we also found a significant association between FCGR2A and the response to infliximab (P=0.035). DHX32 and RGS12 were the most consistently correlated genes with FCGR2A expression in RA synovial fluid macrophages (P<0.001). We found a significant association between the genetic variation at DHX32 (rs12356233, corrected P=0.019) and a nominally significant association between RGS12 and the response to adalimumab (rs4690093, uncorrected P=0.040). In the anti-CCP positive group of patients, we also found a nominally significant association between RGS12 and the response to infliximab (rs2857859, uncorrected P=0.042). Conclusions: In the present study we have validated the FCGR2A association in an independent population, and we have identified new genes associated with the response to anti-TNF therapy in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.
- Author
-
Juli, Antonio, Rodríguez, Jesús, Fernández-Sueiro, José Luis, Gratacós, Jordi, Queir, Rubén, Montilla, Carlos, Torre-Alonso, Juan Carlos, Pérez-Venegas, José Javier, Manrique-Arija, Sara, Muñoz-Fernández, Santiago, González, Carlos, Roig, Daniel, Zarco, Pedro, Erra, Alba, Castañeda, Santos, García, Alicia, Salvador, Georgina, Díaz-Torne, César, Blanco, Ricardo, and Domínguez, Alfredo Willisch
- Abstract
Aim: Variation at PDE3A-SLCO1C1 locus has been recently associated with the response to anti-TNF therapy in rheumatoid arthritis. We undertook the present study to determine whether PDE3A-SLCO1C1 is also associated with the response to anti-TNF therapy in psoriatic arthritis. Patients & methods: Genomic DNA was obtained from 81 psoriatic arthritis patients that had been treated with anti-TNF therapy. PDE3A-SLCO1C1 SNP rs3794271 was genotyped using Taqman realt-time PCR. The clinical response to anti-TNF therapy was measured as the change from baseline in the level of disease activity according to the DAS28 score. Results: A significant association between rs3794271 and anti-TNF response in psoriatic arthritis was found (beta = -0.71; p = 0.0036). Conclusion: PDE3A-SLCO1C1 locus is also associated with response to anti-TNF therapy in psoriatic arthritis. Original submitted 12 May 2014; Revision submitted 18 August 2014 [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis.
- Author
-
Julià, Antonio, Erra, Alba, Palacio, Carles, Tomas, Carlos, Sans, Xavier, Barceló, Pere, and Marsal, Sara
- Subjects
- *
ARTHRITIS , *THERAPEUTICS , *BLOOD hyperviscosity syndrome , *AUTOIMMUNE diseases , *RHEUMATOID arthritis , *GENE expression , *GENETIC regulation , *CYTOLOGICAL techniques , *T cells , *RNA - Abstract
Background: TNF alpha blockade agents like infliximab are actually the treatment of choice for those rheumatoid arthritis (RA) patients who fail standard therapy. However, a considerable percentage of anti-TNF alpha treated patients do not show a significant clinical response. Given that new therapies for treatment of RA have been recently approved, there is a pressing need to find a system that reliably predicts treatment response. We hypothesized that the analysis of whole blood gene expression profiles of RA patients could be used to build a robust predictor to infliximab therapy. Methods and Findings: We performed microarray gene expression analysis on whole blood RNA samples from RA patients starting infliximab therapy (n = 44). The clinical response to infliximab was determined at week 14 using the EULAR criteria. Blood cell populations were determined using flow cytometry at baseline, week 2 and week 14 of treatment. Using complete cross-validation and repeated random sampling we identified a robust 8-gene predictor model (96.6% Leave One Out prediction accuracy, P = 0.0001). Applying this model to an independent validation set of RA patients, we estimated an 85.7% prediction accuracy (75-100%, 95% CI). In parallel, we also observed a significantly higher number of CD4+CD25+ cells (i.e. regulatory T cells) in the responder group compared to the non responder group at baseline (P = 0.0009). Conclusions: The present 8-gene model obtained from whole blood expression efficiently predicts response to infliximab in RA patients. The application of the present system in the clinical setting could assist the clinician in the selection of the optimal treatment strategy in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
26. Fibrilación auricular y ácido zoledrónico en la enfermedad de Paget
- Author
-
Erra, Alba, Moreno, Estefanía, and Rotés, Isabel
- Published
- 2008
- Full Text
- View/download PDF
27. Atrial Fibrillation and Zolendronic Acid in Paget's Disease
- Author
-
Erra, Alba, Moreno, Estefanía, and Rotés, Isabel
- Published
- 2008
- Full Text
- View/download PDF
28. Concordance between direct and indirect measurements of free 25-OH vitamin D.
- Author
-
Peris, Pilar, Filella, Xavier, Monegal, Ana, Guañabens, Nuria, Foj, Laura, Bonet, María, Boquet, Dolors, Casado, Enrique, Cerdá, Dacia, Erra, Alba, Gómez-Vaquero, Carmen, Martínez, Silvia, Montalá, Nuria, Pittarch, Concepción, Kanterewicz, Eduardo, Sala, Miquel, Suris, Xavier, and Carrasco, Josep L.
- Subjects
- *
VITAMIN D , *CARRIER proteins , *BLAND-Altman plot , *BLOOD serum analysis , *ENZYME-linked immunosorbent assay - Abstract
At present, data comparing the quantification methods for measurement of free vitamin D (direct assay [direct 25-OHD F ] and estimated by calculation [calculated 25-OHD F ]), are scarce. The aim of this study was to analyse the concordance between these two methods of 25-OHD F analysis (direct vs. calculated). Methods Serum values of total 25-OHD (25-OHD T ), vitamin D binding protein (DBP) (by R&D Systems ELISA), calculated 25-OHD F (by DBP, albumin and 25-OHD T ) and direct 25-OHD F (by DIAsource ELISA) were analysed in 173 healthy women (aged 35–45 years). Assessment of concordance was evaluated by the Bland-Altman plot and the total deviation index (TDI). Results The mean values of calculated and direct 25-OHD F in these subjects were 5.27 ± 2.5 and 3.83 ± 1.01 pg/mL, respectively. We found significantly lower values of 25-OHD F on comparing subjects with and without vitamin D deficiency, independently of the method used. The total deviation index evaluated by the Bland-Altman plot showed low concordance for both measurements. Only low 25-OHD F levels were concordant. Conclusions This study shows that the concordance between these two methods of 25-OHD F analysis is low and has a concentration dependent bias. Further studies are necessary to clarify the reference values and the indications for 25-OHD F measurement. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis.
- Author
-
Julià A, Gómez A, López-Lasanta M, Blanco F, Erra A, Fernández-Nebro A, Mas AJ, Pérez-García C, Vivar MLG, Sánchez-Fernández S, Alperi-López M, Sanmartí R, Ortiz AM, Fernandez-Cid CM, Díaz-Torné C, Moreno E, Li T, Martínez-Mateu SH, Absher DM, Myers RM, Molina JT, and Marsal S
- Subjects
- Cohort Studies, DNA Methylation, Humans, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha metabolism, Antirheumatic Agents pharmacology, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid genetics
- Abstract
Background: Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease of the joints that has been associated with variation in the peripheral blood methylome. In this study, we aim to identify epigenetic variation that is associated with the response to tumor necrosis factor inhibitor (TNFi) therapy., Methods: Peripheral blood genome-wide DNA methylation profiles were analyzed in a discovery cohort of 62 RA patients at baseline and at week 12 of TNFi therapy. DNA methylation of individual CpG sites and enrichment of biological pathways were evaluated for their association with drug response. Using a novel cell deconvolution approach, altered DNA methylation associated with TNFi response was also tested in the six main immune cell types in blood. Validation of the results was performed in an independent longitudinal cohort of 60 RA patients., Findings: Treatment with TNFi was associated with significant longitudinal peripheral blood methylation changes in biological pathways related to RA (FDR<0.05). 139 biological functions were modified by therapy, with methylation levels changing systematically towards a signature similar to that of healthy controls. Differences in the methylation profile of T cell activation and differentiation, GTPase-mediated signaling, and actin filament organization pathways were associated with the clinical response to therapy. Cell type deconvolution analysis identified CpG sites in CD4+T, NK, neutrophils and monocytes that were significantly associated with the response to TNFi., Interpretation: Our results show that treatment with TNFi restores homeostatic blood methylation in RA. The clinical response to TNFi is associated to methylation variation in specific biological pathways, and it involves cells from both the innate and adaptive immune systems., Funding: The Instituto de Salud Carlos III., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
30. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
- Author
-
Grados D, Martínez-Morillo M, Holgado S, and Erra A
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Humans, Imidazoles therapeutic use, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Zoledronic Acid, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Imidazoles adverse effects, Osteitis Deformans drug therapy
- Published
- 2014
- Full Text
- View/download PDF
31. [Not Available].
- Author
-
Erra A, Moreno E, and Rotés I
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.